Suppr超能文献

用于测试毒性水平的II期两阶段单臂临床试验。

Phase II Two-Stage Single-Arm Clinical Trials for Testing Toxicity Levels.

作者信息

Kim Seongho, Wong Weng Kee

机构信息

Biostatistics Core, Karmanos Cancer Institute/Wayne State University.

Department of Statistics, UCLA.

出版信息

Commun Stat Appl Methods. 2019 Mar;26(2):163-173. doi: 10.29220/CSAM.2019.26.2.163. Epub 2019 Mar 31.

Abstract

Simon's two-stage designs are frequently used in phase II single-arm trials for efficacy studies. In safety studies, a main concern is that there may be too many patients who experience an adverse event. We show that Simon's two-stage designs for efficacy studies can be similarly used to design a two-stage safety study by modifying some of the design parameters. Given the type I and II error rates and the proportion of adverse events experienced in the first stage cohort, we prescribe a procedure whether to terminate the trial or proceed with a stage 2 trial by recruiting additional patients. We study the relationship between a two-stage design with a safety endpoint and an efficacy endpoint and use simulation studies to ascertain their properties. We provide a real-life application and a free R package gen2stage to facilitate direct use of such two-stage designs in a safety study.

摘要

西蒙两阶段设计常用于二期单臂试验的疗效研究。在安全性研究中,一个主要问题是可能有太多患者经历不良事件。我们表明,通过修改一些设计参数,用于疗效研究的西蒙两阶段设计可类似地用于设计两阶段安全性研究。给定第一阶段队列中的I型和II型错误率以及经历不良事件的比例,我们规定一个程序,以确定是终止试验还是通过招募更多患者进行第二阶段试验。我们研究了具有安全性终点和疗效终点的两阶段设计之间的关系,并使用模拟研究来确定它们的特性。我们提供了一个实际应用和一个免费的R包gen2stage,以方便在安全性研究中直接使用这种两阶段设计。

相似文献

1
Phase II Two-Stage Single-Arm Clinical Trials for Testing Toxicity Levels.
Commun Stat Appl Methods. 2019 Mar;26(2):163-173. doi: 10.29220/CSAM.2019.26.2.163. Epub 2019 Mar 31.
2
Modified Simon's minimax and optimal two-stage designs for single-arm phase II cancer clinical trials.
Oncotarget. 2019 Jul 2;10(42):4255-4261. doi: 10.18632/oncotarget.26981.
3
Inclusion of non-inferiority analysis in superiority-based clinical trials with single-arm, two-stage Simon's design.
Contemp Clin Trials Commun. 2020 Nov 28;20:100678. doi: 10.1016/j.conctc.2020.100678. eCollection 2020 Dec.
4
Adaptive sequential design for phase II single-arm oncology trials: an expansion of Simon's design.
J Biopharm Stat. 2025;35(4):500-514. doi: 10.1080/10543406.2024.2341673. Epub 2024 Apr 15.
5
Re-formulating Gehan's design as a flexible two-stage single-arm trial.
BMC Med Res Methodol. 2019 Jan 28;19(1):22. doi: 10.1186/s12874-019-0659-2.
6
Bayesian single-arm phase II trial designs with time-to-event endpoints.
Pharm Stat. 2021 Nov;20(6):1235-1248. doi: 10.1002/pst.2143. Epub 2021 Jun 4.
7
A batch-effect adjusted Simon's two-stage design for cancer vaccine clinical studies.
Biometrics. 2021 Sep;77(3):1075-1088. doi: 10.1111/biom.13358. Epub 2020 Sep 10.
8
Minimax and admissible adaptive two-stage designs in phase II clinical trials.
BMC Med Res Methodol. 2016 Aug 2;16:90. doi: 10.1186/s12874-016-0194-3.
9
Optimal and minimax three-stage designs for phase II oncology clinical trials.
Contemp Clin Trials. 2008 Jan;29(1):32-41. doi: 10.1016/j.cct.2007.04.008. Epub 2007 May 6.
10
Two-stage optimal designs with survival endpoint when the follow-up time is restricted.
BMC Med Res Methodol. 2019 Apr 3;19(1):74. doi: 10.1186/s12874-019-0696-x.

引用本文的文献

1
Editorial: Clinical cancer research in vulnerable populations.
Front Oncol. 2023 Mar 2;13:1166714. doi: 10.3389/fonc.2023.1166714. eCollection 2023.
3
Spatial Two-stage Designs for Phase II Clinical Trials.
Comput Stat Data Anal. 2022 May;169. doi: 10.1016/j.csda.2021.107420. Epub 2022 Jan 6.

本文引用的文献

1
BOP2: Bayesian optimal design for phase II clinical trials with simple and complex endpoints.
Stat Med. 2017 Sep 20;36(21):3302-3314. doi: 10.1002/sim.7338. Epub 2017 Jun 7.
2
Extended two-stage adaptive designs with three target responses for phase II clinical trials.
Stat Methods Med Res. 2018 Dec;27(12):3628-3642. doi: 10.1177/0962280217709817. Epub 2017 May 23.
4
A Bayesian design for phase II clinical trials with delayed responses based on multiple imputation.
Stat Med. 2014 Oct 15;33(23):4017-28. doi: 10.1002/sim.6200. Epub 2014 May 12.
5
Phase II clinical trials with time-to-event endpoints: optimal two-stage designs with one-sample log-rank test.
Stat Med. 2014 May 30;33(12):2004-16. doi: 10.1002/sim.6073. Epub 2013 Dec 13.
7
An evaluation of a Simon 2-Stage phase II clinical trial design incorporating toxicity monitoring.
Contemp Clin Trials. 2011 May;32(3):428-36. doi: 10.1016/j.cct.2011.01.006. Epub 2011 Jan 20.
8
Reducing sample sizes in two-stage phase II cancer trials by using continuous tumour shrinkage end-points.
Eur J Cancer. 2011 May;47(7):983-9. doi: 10.1016/j.ejca.2010.12.007. Epub 2011 Jan 14.
9
Two-stage designs optimal under the alternative hypothesis for phase II cancer clinical trials.
Contemp Clin Trials. 2010 Nov;31(6):572-8. doi: 10.1016/j.cct.2010.07.008. Epub 2010 Aug 1.
10
A predictive probability design for phase II cancer clinical trials.
Clin Trials. 2008;5(2):93-106. doi: 10.1177/1740774508089279.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验